Clinical Trials Browser

NCT05267626 2026-05-18

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Diabetes Mellitus, Insulin-Dependent, 10, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Carcinoma, Merkel Cell

NCT02621021 2026-05-08

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

Phase 2 Recruiting

170 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT05155033 2026-05-08

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

Phase 2 Recruiting

78 enrolled

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT01955460 2026-04-15

Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma

Phase 1 Active not recruiting

34 enrolled

Dermatologic

Melanoma

NCT02830724 2026-04-06

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

Phase 1/2 Recruiting

124 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT04562129 2026-04-01

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Phase 2 Recruiting

29 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT00338377 2026-03-20

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

Phase 2 Active not recruiting

1,230 enrolled

Dermatologic

Melanoma, Meningeal Neoplasms

NCT01659151 2026-02-20

Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma

Phase 2 Completed

17 enrolled 11 charts

Dermatologic

Melanoma, Neoplasm Metastasis

NCT06626256 2025-12-24

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

Phase 1 Withdrawn

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT01005745 2025-12-19

Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma

Phase NA Completed

19 enrolled 7 charts

Dermatologic

Melanoma

NCT01319565 2025-12-19

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...

Phase 2 Completed

102 enrolled 12 charts

Dermatologic

Melanoma, Skin Neoplasms

NCT01701674 2025-12-19

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

Phase NA Completed

13 enrolled 10 charts

Dermatologic

Melanoma, Skin Neoplasms

NCT05296564 2025-10-02

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Phase 1/2 Recruiting

3 enrolled

BreastCNSDermatologicGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Sarcoma, Synovial, Triple Negative Breast Neoplasms

NCT06204991 2025-08-24

ADP-TILIL7

Phase 1 Recruiting

10 enrolled

Dermatologic

Melanoma

NCT02652455 2025-08-19

Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

Phase EARLY_PHASE1 Completed

11 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT06190249 2025-06-05

Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma

Phase 1 Withdrawn

Dermatologic

Melanoma

NCT02278887 2025-03-10

TIL

Phase 3 Completed

168 enrolled

Dermatologic

Melanoma

NCT02500576 2025-01-15

Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma

Phase 2 Completed

18 enrolled 13 charts

Dermatologic

Melanoma

NCT01740557 2024-10-08

Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma

Phase 1/2 Completed

10 enrolled 10 charts

Dermatologic

Melanoma

NCT02027935 2024-10-08

CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma

Phase 2 Completed

16 enrolled 8 charts

Dermatologic

Melanoma

NCT03233828 2024-07-24

IL-2

Phase 3 Terminated

1 enrolled 3 charts

Dermatologic

Melanoma

NCT01856023 2023-12-05

PROCLIVITY02

Phase 4 Terminated

29 enrolled 9 charts

Dermatologic

Melanoma, Neoplasm Metastasis, Skin Neoplasms

NCT06152367 2023-11-30

Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients

Phase 1/2 Completed

90 enrolled

Dermatologic

Melanoma

NCT02748564 2023-08-03

Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

Phase 2 Terminated

10 enrolled 13 charts

Dermatologic

Melanoma

NCT02203604 2023-07-18

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

Phase 2 Terminated

9 enrolled 13 charts

Dermatologic

Melanoma

NCT00003027 2023-06-22

Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma

Phase 3 Completed

482 enrolled

Dermatologic

Melanoma

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Phase 1 Completed

37 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT01993719 2023-01-18

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

Phase 2 Completed

33 enrolled 21 charts

Dermatologic

Melanoma

NCT00945269 2022-11-15

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

Phase 1/2 Terminated

3 enrolled

Dermatologic

Melanoma

NCT01807182 2022-11-10

Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma

Phase 2 Completed

11 enrolled 12 charts

Dermatologic

Melanoma

NCT01946373 2022-10-04

T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma

Phase 1 Unknown

20 enrolled

Dermatologic

Melanoma

NCT03970382 2022-08-18

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

Phase 1 Suspended

21 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Melanoma, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT02111850 2022-03-29